Compare Crispr Therapeutics AG (CRSP) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Goodyear Tire & Rubber Co — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Goodyear Tire & Rubber Co trades at $6.69 (market cap $1.91B). The key difference: Crispr Therapeutics AG is far larger — about 2.6× Goodyear Tire & Rubber Co's market cap. Which is the better fit depends on your goals.
| CRSP | GT | |
|---|---|---|
Market Cap | $4.97B | $1.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $11.54 |
52-Week Low | $44.34 | $5.58 |
Enterprise Value | $3.32B | $9.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Goodyear Tire & Rubber (GT) trades at $6.64, down 2.5% today, with a bearish technical signal and mixed quarterly earnings. The stock shows deep value metrics with a P/E of 4.69 and P/B of 0.64, but fundamental weakness persists with negative net income margin of -11.64% and ROE of -52.56%. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering to strengthen liquidity.
The outlook remains challenging due to operational headwinds and declining revenue, though analyst consensus suggests 32% upside to the $8.75 price target. Key risks include sustained profitability issues and high debt, while potential catalysts include cost-saving initiatives and new contracts like NASA's lunar tire supply.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
